NCT06606301Completed
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma
Immunohistochemical Expression of EGFR in Oral Squamous Cell Carcinoma- A Cross Sectional Study
Source: ClinicalTrials.gov · Last updated 24 Sept 2024
Brief summary (registry, in English)
Oral squamous cell carcinoma (OSCC) is one of the top 10 most common malignancies worldwide. Oral squamous cell carcinoma forms a major health problem in many countries. The reason for the high incidence of oral cavity cancers in Pakistan, and South Asia in general, is the frequent, persistent, and prevalent use of substances classified as oral cancer risk factors. These include betel quid, areca nut, smoking, smokeless tobacco, viral infections such as EBV, HPV, poor oral hygiene (including sharp teeth and decay), ultraviolet (UV) exposure, nutrition, and genetic predisposition. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Associated with worse prognosis, overexpression of EGFR may lead to invasion, cellular migration, enhanced angiogenesis, decreased cell apoptosis, and increased metastatic potential. However, advances in immunotherapy have had a major impact on cancer treatment. This study was exclusively designed to highlight the immunohistochemical detection of expression pattern of EGFR in already diagnosed cases of lip and OSCC in histopathology dept of AFIP and its correlation with the grade of the tumor. In this study, contact details of all diagnosed cases of SCC of lips and oral cavity from June to November 2023 were taken from the archives of Histopathology department. The patients were contacted for consent approval for participation. The data was collected (as per proforma attached), including demographic details, location of tumor. Blocks were retrieved, grade of tumor was identified followed by the application of EGFR marker. Patterns of expression of EGFR were evaluated and compared with grade of tumor to strengthen the correlation of this association.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 61 (actual)
- First submitted
- 18 Sept 2024
- Start date
- Aug 2023
- Primary completion date
- Nov 2023
- Lead sponsor
- Combined Military Hospital, Pakistan
- Diseases
- Head and neck cancer, Childhood cancers
- NCT number
- NCT06606301
What you commit to
- Study type: Observational
- Participants enrolled: 61
- From Aug 2023 to the primary completion date, Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All specimen of patients having received chemotherapy/radiotherapy prior to surgery
Other
- All specimens with inadequate or poor fixation.
- Very scanty tissue biopsies or those with extensive tissue necrosis
- Patients not consenting to be the part of the study
Who the study is looking for
- Cases of surgically treated lip/oral cavity squamous cell carcinoma
- Patients of all age groups, irrespective of their gender
- Patients with a tumor located in the tongue, inferior and superior gingivae, buccal mucosa, floor of the mouth, palate, alveolus and vestibule(buccal/labial and mandible/maxilla)
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Armed Forces Institute of Pathology, Combined Military Hospital Coordinator of this site? Confirm its status | Rawalpindi | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.